Search details
1.
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.
Blood
; 141(18): 2194-2205, 2023 05 04.
Article
in English
| MEDLINE | ID: mdl-36796016
2.
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
Blood
; 142(26): 2327-2331, 2023 12 28.
Article
in English
| MEDLINE | ID: mdl-37738563
3.
Unmet mental health needs in patients with advanced B-cell lymphomas.
Palliat Support Care
; 20(3): 328-333, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35713350
4.
Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations.
Blood
; 132(7): e13-e23, 2018 08 16.
Article
in English
| MEDLINE | ID: mdl-29967128
5.
Surveillance scanning in lymphoma.
Clin Adv Hematol Oncol
; 17(6): 352-359, 2019 Jun.
Article
in English
| MEDLINE | ID: mdl-31437139
6.
DLBCL Cell of Origin: What Role Should It Play in Care Today?
Oncology (Williston Park)
; 32(9): 445-9, 2018 09 15.
Article
in English
| MEDLINE | ID: mdl-30248164
7.
Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials.
Br J Haematol
; 179(2): 242-245, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28677889
8.
Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee.
Br J Haematol
; 184(3): 466-467, 2019 02.
Article
in English
| MEDLINE | ID: mdl-29377067
9.
Lymphoma "benchmark" or "bench-smudge"?
Blood
; 130(16): 1778-1779, 2017 10 19.
Article
in English
| MEDLINE | ID: mdl-29051150
10.
XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.
Cancer Res
; 84(1): 101-117, 2024 01 02.
Article
in English
| MEDLINE | ID: mdl-37801604
11.
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
J Clin Oncol
; 41(2): 336-342, 2023 01 10.
Article
in English
| MEDLINE | ID: mdl-35787017
12.
The Uncertainties of Rituximab and Related Therapies, 20 Years After Approval.
Oncology (Williston Park)
; 31(5): 412, 414, 2017 05 15.
Article
in English
| MEDLINE | ID: mdl-28516440
13.
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.
Clin Lymphoma Myeloma Leuk
; 22(7): e435-e442, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35093285
14.
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
Lancet Haematol
; 8(11): e818-e827, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34634256
15.
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
Blood Adv
; 5(22): 4762-4770, 2021 11 23.
Article
in English
| MEDLINE | ID: mdl-34581757
16.
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma.
Leuk Lymphoma
; 62(7): 1629-1638, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33586581
17.
Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma.
J Palliat Med
; 23(6): 832-837, 2020 06.
Article
in English
| MEDLINE | ID: mdl-31633432
18.
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA.
Blood Adv
; 4(8): 1589-1593, 2020 04 28.
Article
in English
| MEDLINE | ID: mdl-32298429
19.
Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma.
Blood Adv
; 8(6): 1464-1468, 2024 Mar 26.
Article
in English
| MEDLINE | ID: mdl-38266151
20.
Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.
Cell Cycle
; 15(17): 2241-7, 2016 Sep.
Article
in English
| MEDLINE | ID: mdl-27419806